Shots:
Merck has entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals for HRS-5346
As per the deal, Merck has obtained exclusive rights to develop, manufacture & commercialize HRS-5346 globally excl. Greater China region in exchange for $200M upfront & ~$1.77B in development, regulatory & commercial milestones, along with net sales-based royalties; closing expected…
